AKT1 and neoplasm: Beyond immunosuppression, KYN and its metabolites activate oncogenic signaling pathways such as MAPK and PI3K/AKT, thereby promoting tumor cell proliferation, survival, epithelial–mesenchymal transition (EMT), and metastatic potential (45).